Bogutai® (Parathyroid hormone 1-34 analogue or rhPTH (1-34)) is effective in treating osteoporosis and bone pain, and has the potential to reduce fracture incidence by improving bone qualities and increasing bone density.
In clinical trials, Bogutai® has been shown to be effective in stimulating new bone formation on quiescent bone surface, which is treatment mechanism rarely seen in the market filled with products to inhibit bone absorption.
Bogutai® can rapidly improve bone quality and restore bone density during treatment within six months, reducing the risk of fractures and bone pain, especially in patients with moderate to severe osteoporosis.
Effective
Bogutai®'s pharmacological, non-clinical and clinical trials have confirmed that its therapeutic effect is consistent with Forteo. Bogutai® is effective in relieving pain, increasing bone density, reducing the risk of fractures, without any side effects.
High compliance rate
Bogutai® is the first domestic manufactured PTH Liquid in China to use a disposable injection pen, which can provide patients with a comfortable operation experience, effectively improve the patient compliance rate, and also reduce the risk and loss of drugs in the transportation and storage process.
Excellent cost performance
With cost advantages, Bogutai® will adopt a effective and flexible pricing strategy to quickly increase product penetration and market share.
The marketing application for Bogutai® was accepted by the NMPA on June 28, 2022. Bogutai® is expected to be available for sale in 2023. In addition, a third generation oral dosage form of UNI-PTH is under preparation.
Huge population
China is the country with the largest number of osteoporosis in the world. At present, the population aged 60 and above in China is about 264 million, accounting for 18.70%. The trend of population aging will continue to deepen.
High prevalence
The results of the epidemiological survey of osteoporosis in China showed that osteoporosis has become an important health problem for the elderly in China. The prevalence of osteoporosis in people over 50 years old was 19.2%, and the prevalence of osteoporosis in middle-aged and elderly women was particularly serious, and the prevalence of osteoporosis in women over 65 years old was as high as 51.6%.
Huge market size
According to public data, the overall size of the global orthopedic market has exceeded 50 billion US dollars. According to CICC International Consulting, the sales of chemical drugs for osteoporosis and calcium supplementation in China exceeded RMB 26 billion in 2018, and the compound annual growth rate from 2016 to 18 was 10.28%, which was higher than the growth level of the overall drug market in the same period.
